BLOGS >

Voices

Archives for December 2010

RSS
Engage with independent insights, opinions, and analysis from an array of leaders in cardiology.
Avatar of CardioExchange Editors, Staff

Looking Forward to 2011 (28 Dec 2010)

CardioExchange Editors, Staff

CardioExchange invited a wide range of members−researchers, teachers, private practice clinicians, and fellows−to offer predictions for 2011. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts. The same CardioExchange members give us their impressions of the most important developments in cardiology in 2010, and you can see a summary of those here. What are your predictions for the year? Where have our Nostradamus’ gone wrong? Steven E Nissen, MD 1. Federal investigation of overuse of stents 2. ACC announces that… Continue Reading

Avatar of CardioExchange Editors, Staff

A Look Back at 2010 (24 Dec 2010)

CardioExchange Editors, Staff

CardioExchange invited a wide range of members−researchers, teachers, private practice clinicians, and fellows−to give us their impressions of the most important developments in cardiology in 2010. We summarize their lists here and offer a running scorecard. Click the authors’ names to read the full posts.  The same CardioExchange members offered predictions for 2011, and you can see a summary of those here. Also, for comparison, check out the AHA list of the top 10 advances in cardiovascular research this year. What would your choices have been? Any sins of inclusion… Continue Reading

Avatar of Thad F Waites, MD, FACC

Thad Waites: Looking Back at 2010 and Ahead to 2011 (23 Dec 2010)

Thad F Waites, MD, FACC

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. Dabigatran, which has been released, and the other oral thrombin inhibitors, which will be released: Imagine, we finally have  a replacement for warfarin, in the appropriate situations. For the patients (and ignoring the cost for the moment), it will be a big improvement — no blood testing, no dietary changes, and take just two pills a day with no… Continue Reading

Avatar of James

James De Lemos: Looking Back at 2010 and Ahead to 2011 (23 Dec 2010)

James de Lemos, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: ACGME releases new work hour rules. Although these new guidelines are not specifically focused on cardiology training, they promise to impact all cardiologists in teaching facilities. The long-term impact of these changes will take years to fully understand, but are likely to continue the erosion of professionalism and competence among trainees. Aldosterone antagonists continue their winning streak… Continue Reading

Avatar of Barry M. Massie, BA (Harvard), MD (Columbia P&S)

Barry Massie: Looking Back at the Year in Heart Failure (23 Dec 2010)

Barry M. Massie, BA (Harvard), MD (Columbia P&S)

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the most important cardiology-related events of the past year. Barry Massie has focused on heart failure, providing us with his choice of the four most important stories of 2010. 1. Aldosterone antagonists continue their winning streak: Following the convincing reductions in mortality and morbidity with spironolactone in severe heart failure (NYHA class III/IV) in the RALES trial and in the EPHESUS trial with eplerenone in patients with acute MI and LV dysfunction, we saw similar striking reductions (37%) in… Continue Reading

Avatar of John

John Brush: Looking Back at 2010 and Ahead to 2011 (23 Dec 2010)

John E Brush, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. The PARTNER Trial demonstrated the efficacy of transcatheter aortic valve implantation for patients deemed too high risk for conventional cardiac surgery.  This intervention will be a game-changer for the treatment of patients with aortic stenosis, but raises mind-boggling questions about where and by whom the procedure should be performed, proper case-selection, cost-effectiveness, self-referral…the questions go on… Continue Reading

Avatar of John Mandrola, MD, FACC

John Mandrola: Looking Back at 2010 and Ahead to 2011 (23 Dec 2010)

John Mandrola, MD, FACC

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. By far, the number one heart story of 2010 was the release of the novel blood-thinning drug, dabigatran (Pradaxa), for the prevention of stroke in atrial fibrillation (AF). Until this October, the only way to reduce stroke risk in AF was warfarin — the active ingredient of rat poison. Assuming that there aren’t any post-market surprises, Pradaxa… Continue Reading

Avatar of John

John Ryan: Looking Back at 2010 and Ahead to 2011 (22 Dec 2010)

John Ryan, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment: Ten years after the initial decoding of the human genome, we felt we finally had a genetic test and a drug with clinical applicability. However, this study and others cast doubt on the ability to predict response to anti-platelet therapy, demonstrating that we still have a lot… Continue Reading

Avatar of Larry Husten, PHD

Deepak Bhatt: Looking Back at 2010 and Ahead to 2011 (22 Dec 2010)

Deepak L. Bhatt, MD, MPH

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. PARTNER: Transcatheter aortic valve implantation significantly improved symptoms and reduced mortality in patients with severe aortic stenosis who were not candidates for surgery. The treatment of valvular heart disease is forever changed. 2. RAFT: CRT when added to an ICD reduced heart failure hospitalizations and reduced mortality in an easily identified group of patients with heart… Continue Reading

Avatar of Richard A. Lange, MD, MBA

Rick Lange & David Hillis: Looking Back at 2010 and Ahead to 2011 (21 Dec 2010)

L. David Hillis, MD and Richard A. Lange, MD, MBA

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. Stenting Versus Endarterectomy for Carotid-Artery Stenosis: In patients with carotid artery stenoses, stenting and endarterectomy were associated with similar rates of the primary composite endpoint — periprocedural stroke, MI, or death and subsequent ipsilateral stroke.  However, the incidence of periprocedural stroke was lower in the endarterectomy group, whereas the incidence of periprocedural MI was lower in… Continue Reading